-+ 0.00%
-+ 0.00%
-+ 0.00%

Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026

Benzinga·07/15/2026 21:04:45
Listen to the news

SEC Filing